We searched PubMed to find studies on the use of SGLT2 inhibitors in patients with type 2 diabetes in the post-myocardial infarction phase using the terms “myocardial infarction”, “diabetes mellitus”, in addition to “SGLT2-inhibitor”, “sodium-glucose cotransporter 2 inhibitor”, “canagliflozin”, “empagliflozin”, and “dapagliflozin” from Jan 1, 2010 to Dec 1, 2023. The gene discussed is SLC5A2; the disease is diabetes mellitus.